KR102410986B1 - Ｆｇｆ－１８ 화합물 투여 처방 - Google Patents

Ｆｇｆ－１８ 화합물 투여 처방 Download PDF

Info

Publication number
KR102410986B1
KR102410986B1 KR1020167025246A KR20167025246A KR102410986B1 KR 102410986 B1 KR102410986 B1 KR 102410986B1 KR 1020167025246 A KR1020167025246 A KR 1020167025246A KR 20167025246 A KR20167025246 A KR 20167025246A KR 102410986 B1 KR102410986 B1 KR 102410986B1
Authority
KR
South Korea
Prior art keywords
fgf
cartilage
compound
treatment
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167025246A
Other languages
English (en)
Korean (ko)
Other versions
KR20160116001A (ko
Inventor
크리스토프 하. 라델
한스 게링
Original Assignee
메르크 파텐트 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메르크 파텐트 게엠베하 filed Critical 메르크 파텐트 게엠베하
Publication of KR20160116001A publication Critical patent/KR20160116001A/ko
Application granted granted Critical
Publication of KR102410986B1 publication Critical patent/KR102410986B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020167025246A 2014-02-20 2015-02-20 Ｆｇｆ－１８ 화합물 투여 처방 Active KR102410986B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14000600.8 2014-02-20
EP14000600 2014-02-20
PCT/EP2015/053631 WO2015124731A1 (en) 2014-02-20 2015-02-20 Fgf-18 compound dosing regimen

Publications (2)

Publication Number Publication Date
KR20160116001A KR20160116001A (ko) 2016-10-06
KR102410986B1 true KR102410986B1 (ko) 2022-06-17

Family

ID=50151088

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020167025246A Active KR102410986B1 (ko) 2014-02-20 2015-02-20 Ｆｇｆ－１８ 화합물 투여 처방
KR1020167025245A Active KR102410988B1 (ko) 2014-02-20 2015-02-20 Ｆｇｆ－１８ 화합물 투여 처방

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020167025245A Active KR102410988B1 (ko) 2014-02-20 2015-02-20 Ｆｇｆ－１８ 화합물 투여 처방

Country Status (25)

Country Link
US (2) US9889179B2 (enExample)
EP (2) EP3107559B1 (enExample)
JP (2) JP6431082B2 (enExample)
KR (2) KR102410986B1 (enExample)
CN (2) CN106232622A (enExample)
AR (2) AR099510A1 (enExample)
AU (2) AU2015220777B2 (enExample)
BR (2) BR112016018696A2 (enExample)
CA (1) CA2938791A1 (enExample)
DK (2) DK3119417T3 (enExample)
ES (2) ES2688551T3 (enExample)
HR (2) HRP20181572T1 (enExample)
HU (1) HUE040350T2 (enExample)
IL (2) IL247083B (enExample)
LT (2) LT3107559T (enExample)
MX (2) MX2016010872A (enExample)
NZ (1) NZ723148A (enExample)
PL (2) PL3119417T3 (enExample)
PT (2) PT3107559T (enExample)
RS (2) RS57853B1 (enExample)
RU (2) RU2700582C2 (enExample)
SG (2) SG11201606502YA (enExample)
SI (2) SI3119417T1 (enExample)
WO (2) WO2015124727A1 (enExample)
ZA (2) ZA201605547B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102920449B1 (ko) 2023-03-29 2026-02-03 주식회사 아이프로테인테라퓨틱스 인터류킨-1 수용체 길항제 변이체 및 이의 용도

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3107559B1 (en) 2014-02-20 2018-07-11 Merck Patent GmbH Fgf-18 compound dosing regimen
BR112016018681B1 (pt) 2014-02-20 2021-01-05 Merck Patent Gmbh sistema de distribuição de substâncias que compreende pelo menos um material polimérico formador de uma matriz e um fármaco anabólico, processo de produção do mesmo e artigo de manufatura
WO2016120387A1 (en) 2015-01-29 2016-08-04 Ares Trading S.A. Immunoassays for high positively charged proteins
DK3419625T3 (da) 2016-02-22 2021-07-12 Novartis Ag Fremgangsmåder til anvendelse af fxr-agonister
PL3688468T3 (pl) 2017-09-29 2022-07-18 Merck Patent Gmbh Biomarkery stanu zapalnego do przewidywania odpowiedzi na związek fgf-18
DK3687558T3 (da) 2017-09-29 2022-06-20 Merck Patent Gmbh Metaboliske biomarkører til forudsigelse af modtageligheden på fgf-18 forbindelse
IL281333B2 (en) 2018-09-10 2025-11-01 Merck Patent Gmbh A method for reducing risk in a clinical trial
US20220184180A1 (en) * 2019-02-08 2022-06-16 Merck Patent Gmbh Treatment of patients at risk of rapid progression of osteoarthritis
WO2025077768A1 (en) * 2023-10-11 2025-04-17 Sichuan Real & Best Biotech Co., Ltd. Compositions and methods for treating arthritis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060009389A1 (en) 2004-07-06 2006-01-12 Moore Emma E Pharmaceutical composition comprising FGF18 and IL-1 antagonist and method of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040136970A1 (en) * 2002-10-07 2004-07-15 Ellsworth Jeff L. Methods for administering FGF18
US20070243132A1 (en) * 2005-12-22 2007-10-18 Apollo Life Sciences Limited Transdermal delivery of pharmaceutical agents
CA2658511C (en) 2006-08-25 2019-02-19 Ares Trading S.A. Use of fgf-18 compound to treat cartilage disorders
ZA200900426B (en) * 2006-08-25 2010-04-28 Ares Trading Sa Treatment of cartilage disorders with FGF-18
DE102006043260A1 (de) * 2006-09-11 2008-03-27 Krones Ag Etikettieranlage
EP2688890B1 (en) * 2011-03-22 2017-08-30 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
EP3107559B1 (en) 2014-02-20 2018-07-11 Merck Patent GmbH Fgf-18 compound dosing regimen
AU2015220781B2 (en) 2014-02-20 2018-05-24 Merck Patent Gmbh FGF-18 in graft transplantation and tissue engineering procedures
BR112016018681B1 (pt) 2014-02-20 2021-01-05 Merck Patent Gmbh sistema de distribuição de substâncias que compreende pelo menos um material polimérico formador de uma matriz e um fármaco anabólico, processo de produção do mesmo e artigo de manufatura

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060009389A1 (en) 2004-07-06 2006-01-12 Moore Emma E Pharmaceutical composition comprising FGF18 and IL-1 antagonist and method of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Jonathon Power et al., JOURNAL OF ORTHOPAEDIC RESEARCH, vol.32, no.5, pp.669-676(First published : 16 January 2014)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102920449B1 (ko) 2023-03-29 2026-02-03 주식회사 아이프로테인테라퓨틱스 인터류킨-1 수용체 길항제 변이체 및 이의 용도

Also Published As

Publication number Publication date
EP3107559A1 (en) 2016-12-28
EP3107559B1 (en) 2018-07-11
JP6431082B2 (ja) 2018-11-28
BR112016018696A2 (pt) 2017-10-17
AU2015220777A1 (en) 2016-09-01
ES2688551T3 (es) 2018-11-05
MX2016010872A (es) 2016-11-17
AR099558A1 (es) 2016-08-03
KR20160116001A (ko) 2016-10-06
PL3107559T3 (pl) 2019-01-31
KR20160116000A (ko) 2016-10-06
US9889179B2 (en) 2018-02-13
PT3119417T (pt) 2018-10-31
PL3119417T3 (pl) 2019-01-31
IL247084B (en) 2019-09-26
JP2017512194A (ja) 2017-05-18
AU2015220773B2 (en) 2020-10-08
PT3107559T (pt) 2018-10-31
SI3107559T1 (sl) 2018-11-30
LT3119417T (lt) 2018-10-25
KR102410988B1 (ko) 2022-06-17
DK3119417T3 (en) 2018-10-22
US20170072017A1 (en) 2017-03-16
AU2015220773A1 (en) 2016-09-01
LT3107559T (lt) 2018-10-25
ZA201605548B (en) 2018-12-19
IL247083A0 (en) 2016-09-29
CN106456713A (zh) 2017-02-22
SG11201606505UA (en) 2016-09-29
NZ723148A (en) 2022-08-26
IL247084A0 (en) 2016-09-29
BR112016018685A2 (pt) 2017-10-17
WO2015124727A1 (en) 2015-08-27
RU2691946C2 (ru) 2019-06-19
SI3119417T1 (sl) 2018-11-30
AU2015220777B2 (en) 2020-10-22
JP2017507142A (ja) 2017-03-16
ES2689071T3 (es) 2018-11-08
RU2016137292A3 (enExample) 2018-09-17
HRP20181572T1 (hr) 2018-11-30
DK3107559T3 (en) 2018-10-15
EP3119417B1 (en) 2018-07-11
IL247083B (en) 2019-09-26
NZ723139A (en) 2022-12-23
WO2015124731A1 (en) 2015-08-27
HRP20181570T1 (hr) 2018-11-30
ZA201605547B (en) 2019-09-25
US20170056474A1 (en) 2017-03-02
RU2016137289A3 (enExample) 2018-10-19
US9724388B2 (en) 2017-08-08
RS57709B1 (sr) 2018-12-31
MX2016010871A (es) 2016-11-17
AR099510A1 (es) 2016-07-27
RS57853B1 (sr) 2018-12-31
CN106232622A (zh) 2016-12-14
EP3119417A1 (en) 2017-01-25
SG11201606502YA (en) 2016-09-29
RU2016137289A (ru) 2018-03-21
HUE040350T2 (hu) 2019-03-28
RU2700582C2 (ru) 2019-09-18
RU2016137292A (ru) 2018-03-21
CA2938791A1 (en) 2015-08-27
CA2938793A1 (en) 2015-08-27
JP6431083B2 (ja) 2018-11-28

Similar Documents

Publication Publication Date Title
KR102410986B1 (ko) Ｆｇｆ－１８ 화합물 투여 처방
KR101419961B1 (ko) Ｆｇｆ-18 로 연골 질환의 치료
CN101505787B (zh) 软骨障碍的治疗
CA2938793C (en) Fgf-18 compound dosing regimen
RU2745453C2 (ru) Комбинированная композиция, содержащая соединение fgf-18
HK1231754A1 (zh) Fgf-18化合物给药方案
HK1231895A1 (en) Fgf-18 compound dosing regimen
HK1129852B (en) Treatment of cartilage disorders
HK1129852A (en) Treatment of cartilage disorders

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160912

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200220

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210803

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220315

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220615

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220615

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20250520

Start annual number: 4

End annual number: 4